NEW YORK--(BUSINESS WIRE)--Broadwood Partners, L.P. and its affiliates ("Broadwood†or "we†), which together own 30.2% of the outstanding common stock of STAAR Surgical Company ("STAAR†or the "Company†) (NASDAQ: STAA), today responded to the fourth postponement of STAAR's Special Meeting of Shareholders (the "Special Meeting†) in connection with the proposed acquisition of STAAR by Alcon Inc. ("Alcon†) (NYSE: ALC). The Special Meeting, which was originally scheduled to be held on October 23, 2. ...

LAKE FOREST, Calif.--(BUSINESS WIRE)--STAAR Surgical Company (NASDAQ: STAA), the manufacturer of the Implantable Collamer® Lens (ICL) today announced that Alcon (SIX/NYSE: ALC) has exercised its right under the Alcon merger agreement to require STAAR to adjourn its Special Meeting of Stockholders in connection with the Alcon merger agreement (the "Special Meeting†). As a result, the Special Meeting, which was scheduled for December 19, 2025 at 8:30 a.m. Pacific Time, has been adjourned to January 6, 2026 ...

As I write this, it is the middle of December, and the Alcon Inc. ( ALC ) acquisition of LENSAR, INC. ( LNSR ) remains unfinished, despite the two firms earlier hoping to complete it by the endRobert F. Abbott has been investing his family’s accounts since 1995, and in 2010 added options, mainly covered calls and collars with long stocks. He is a freelance writer, and his projects include a website that provides information for new and intermediate-level mutual fund investors. A resident of Airdrie, Alberta ...

Expresses Disappointment in the Board's and Management's Continued Pursuit of Ill-advised Deal CHARLOTTE, N.C., Dec. 17, 2025 /PRNewswire/ -- Defender Capital ("Defender" or "we"), a long-term shareholder of STAAR Surgical Company ("STAAR" or the "Company") (NASDAQ: STAA) owning approximately 1.5% of the Company's outstanding common stock, today issued the following statement reiterating its intention to vote AGAINST the Company's proposed sale to Alcon Inc. ("Alcon") (NYSE: ALC) and expressing its disappoi ...

NEW YORK--(BUSINESS WIRE)--Broadwood Partners, L.P. and its affiliates (collectively, "Broadwood†) today issued the following letter to the Board of Directors (the "Board†) of STAAR Surgical Company ("STAAR†or the "Company†) (NASDAQ: STAA). Broadwood, which owns 30.2% of STAAR's outstanding common stock, continues to urge its fellow shareholders to vote "AGAINST†the proposed acquisition of STAAR by Alcon Inc. ("Alcon†) (NYSE: ALC). Shareholders can find additional information at www.LetSTAARS. ...

LAKE FOREST, Calif.--(BUSINESS WIRE)--STAAR Surgical Company (NASDAQ: STAA), the global leader in phakic IOLs with the EVO family of Implantable Collamer® Lenses (EVO ICL™) for vision correction, today issued the following open letter to STAAR stockholders: Dear STAAR Surgical Stockholders: The Special Meeting of Stockholders to vote on the amended agreement with Alcon Inc. (SIX/NYSE: ALC) is just days away. How you vote at the Special Meeting will greatly influence the value of your shares. Yo. ...

Core Viewpoint - STAAR Surgical Company has amended its merger agreement with Alcon, offering stockholders $30.75 per share, which represents a 74% premium to the 90-day Volume Weighted Average Price and a 66% premium to the closing price on August 4, 2025 [1][2]. Group 1: Merger Agreement Details - The revised merger agreement with Alcon is set to provide STAAR stockholders with $30.75 per share in cash if the transaction is completed [1]. - Independent proxy advisory firm Institutional Shareholder Services (ISS) recommends that STAAR stockholders vote "FOR" the Alcon transaction, citing improved terms and reduced downside risks [2]. - The STAAR Board of Directors also urges stockholders to vote "FOR" the merger to protect their investment value [3]. Group 2: Analyst Insights - Analysts from BTIG suggest that STAAR shareholders should accept the offer, warning of potential significant declines in share value if the deal does not go through [5]. - Canaccord Genuity notes that the expiration of the "go-shop" period revealed limited interest from other potential acquirers, indicating that the revised terms are likely to satisfy shareholders [5]. - Mizuho highlights that the $1.6 billion valuation of the transaction is approximately 4.5 times the forward EV/Sales based on projected revenues, which aligns with industry standards for similar companies [5]. Group 3: Company Background - STAAR Surgical is a leader in implantable phakic intraocular lenses, focusing solely on ophthalmic surgery since 1982, and has sold over 3 million ICLs globally [7]. - The company operates research, development, manufacturing, and packaging facilities in California and Switzerland, emphasizing its commitment to advanced vision correction solutions [7].

LAKE FOREST, Calif.--(BUSINESS WIRE)--STAAR Surgical Company (NASDAQ: STAA) ("STAAR†), the global leader in phakic IOLs with the EVO family of Implantable Collamer® Lenses (EVO ICLâ"¢) for vision correction, today announced that leading independent proxy advisory firm Institutional Shareholder Services ("ISS†) has issued a new report and revised its recommendation with respect to STAAR's merger with Alcon. ISS is now recommending that all STAAR stockholders vote "FOR†STAAR's amended merger agree. ...

NEW YORK--(BUSINESS WIRE)--Broadwood Partners, L.P. and its affiliates ("Broadwood†or "we†) today announced that Glass, Lewis & Co., LLC ("Glass Lewis†), a leading independent proxy advisory firm, has reaffirmed its recommendation that shareholders of STAAR Surgical Company ("STAAR†or the "Company†) (NASDAQ: STAA) should vote "AGAINST†the proposed acquisition of STAAR by Alcon Inc. ("Alcon†) (NYSE: ALC). Glass Lewis concluded in its report that "we do not believe there exists persuasive. ...

Core Viewpoint - BofA Securities has downgraded Alcon Inc. from Buy to Underperform and reduced its price target from $100 to $75 due to a negative outlook influenced by market softness, increased competition, and multiple guidance cuts affecting sentiment [1] Group 1: Market Conditions - The downgrade reflects a year characterized by market softness and heightened competition, which have negatively impacted Alcon's performance [1] - Analysts believe that consensus forecasts for improving confidence into 2026 are overly optimistic, expecting a sharp rebound and market share gains despite limited visibility [2] Group 2: Financial Estimates - BofA's fiscal 2026 and 2027 EPS estimates are 4% and 7% below consensus, indicating a cautious outlook [2] - The firm has cut its fiscal 2026 EPS by 8% and adjusted valuation multiples based on higher WACC assumptions and adverse market conditions [3] Group 3: Valuation Metrics - Despite a 20% valuation pullback from 2024 highs, Alcon's forward P/E ratio remains around 25x, which is considered elevated given the expected EPS CAGR of less than 10% from 2025 to 2027 [3]